Literature DB >> 16678430

3-Aza-6,8-dioxabicyclo[3.2.1]octanes as new enantiopure heteroatom-rich tropane-like ligands of human dopamine transporter.

Nicoletta Cini1, Elisa Danieli, Gloria Menchi, Andrea Trabocchi, Anna Bottoncetti, Silvia Raspanti, Alberto Pupi, Antonio Guarna.   

Abstract

CNS diseases such as Parkinson, schizophrenia, and attention deficit hyperactivity disorder (ADHD) are characterized by a significant alteration of dopamine transporter (DAT) density. Thus, the development of compounds that are able to selectively interact with DAT is of great interest. Herein we describe the design and synthesis of a new set of 3-aza-6,8-dioxabicyclo[3.2.1]octanes having a tropane-like structure with additional heteroatoms at positions 3 and 6. The compounds were evaluated for their in vitro receptor binding properties toward human dopamine (hDAT) and serotonin (hSERT) transporters using [3H]WIN35,428 and [3H]citalopram as specific radioligands, respectively. Biological assays revealed that some compounds having the N-3 atom substituted with aryl groups possess significant affinity and selectivity for monoamine transporters, and in particular, compound 5d displayed an IC50 of 21 nM toward DAT, and a good selectivity toward SERT (IC50=1042 nM). These results suggest that 3-aryl-3-aza-6,8-dioxabicyclo[3.2.1]octanes may represent a new class of DAT ligands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16678430     DOI: 10.1016/j.bmc.2006.04.019

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Singular value decomposition analysis of the torsional angles of dopamine reuptake inhibitor GBR 12909 analogs: effect of force field and charges.

Authors:  Deepangi Pandit; Anna Fiorentino; Supreet Bindra; Carol A Venanzi
Journal:  J Mol Model       Date:  2010-09-14       Impact factor: 1.810

2.  Relations between Effects and Structure of Small Bicyclic Molecules on the Complex Model System Saccharomyces cerevisiae.

Authors:  Matteo Brilli; Andrea Trabocchi; Tobias Weil; Duccio Cavalieri; Irene Stefanini
Journal:  Front Pharmacol       Date:  2017-03-30       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.